Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. (AVTX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · AVTX · as of Sep 30, 2025
Ownership Breakdown
70
Institutional Holders
▲ 35 vs Q2
$194.69M
Total Inst. Value
▲ $155.55M vs Q2
11.29M
Shares Outstanding
freeFloat 95.96%
15.32M
13F Shares Held
▲ 7.47M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
AVTX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BVF INC/IL pharmaceutical preparations | 1.36M | 9.68% | 9.68% | $17.23B | Nov 14, 2025 | ▲ 327.2K |
ORBIMED ADVISORS LLC pharmaceutical preparations | 1.35M | 9.64% | 9.64% | $17.15B | Nov 14, 2025 | ▲ 382.3K |
NANTAHALA CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 1.24M | 8.82% | 8.82% | $15.70B | Nov 14, 2025 | ▲ 240.0K |
POINT72 ASSET MANAGEMENT, L.P. pharmaceutical preparations | 1.05M | 7.53% | 7.53% | $13.40B | Nov 14, 2025 | NEW |
AFFINITY ASSET ADVISORS, LLC pharmaceutical preparations | 1.01M | 7.19% | 7.19% | $12.79B | Nov 13, 2025 | ▲ 398.3K |
CALIGAN PARTNERS LP pharmaceutical preparations | 833.3K | 5.95% | 5.95% | $10.59B | Nov 14, 2025 | NEW |
BALYASNY ASSET MANAGEMENT L.P. pharmaceutical preparations | 817.4K | 5.84% | 5.84% | $10.39B | Nov 14, 2025 | NEW |
BANK OF AMERICA CORP /DE/ pharmaceutical preparations | 605.8K | 5.59% | 5.59% | $7.70B | Feb 3, 2026 | ▲ 199.3K |
SILVERARC CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 720.9K | 5.15% | 5.15% | $9.16B | Nov 12, 2025 | NEW |
VANGUARD GROUP INC pharmaceutical preparations | 692.6K | 4.95% | 4.95% | $8.80B | Nov 7, 2025 | ▲ 525.7K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
12
Increased
+2.63M shares27
New Positions
first time holders7
Decreased
−985.8K shares0
Sold Out
fully exitedNet shares change (top 50)
+1.64M
+2.63M / −985.8K
Net new holders
+32
27 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
AVTX insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
23
Buy transactions
40
Sell transactions
0.57
Buy/Sell ratio
$1M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Lind Kevin Robert director | Jun 2, 2026 | Award | 20,100 | $13.96 | $280.6K | 20.1K | Form 4 ↗ |
Truex Samantha director | Jun 2, 2026 | Award | 20,100 | $13.96 | $280.6K | 20.1K | Form 4 ↗ |
KAPLAN GILLA director | Jun 2, 2026 | Award | 20,100 | $13.96 | $280.6K | 20.1K | Form 4 ↗ |
KANTOFF AARON director | Jun 2, 2026 | Award | 20,100 | $13.96 | $280.6K | 20.1K | Form 4 ↗ |
Heffernan Michael Thomas director | Jun 2, 2026 | Award | 29,500 | $13.96 | $411.8K | 29.5K | Form 4 ↗ |
Jain Rita director | Jun 2, 2026 | Award | 20,100 | $13.96 | $280.6K | 20.1K | Form 4 ↗ |
Doyle Mittie Chief Medical Officer | May 28, 2026 | Sale | 679 | $16.00 | $10.9K | 47.1K | Form 4 ↗ |
Riley Jennifer Chief Strategy Officer | May 21, 2026 | Award | 34,200 | — | — | 36.9K | Form 4 ↗ |
Sullivan Christopher Ryan Chief Financial Officer | May 21, 2026 | Award | 39,900 | — | — | 40.3K | Form 4 ↗ |
VARKI PAUL Chief Legal Officer | May 21, 2026 | Award | 24,300 | — | — | 27.9K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Avalo Therapeutics, Inc. (AVTX) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 4.04%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Avalo Therapeutics, Inc. is BVF INC/IL, holding approximately 1.36 million shares — equal to 9.68% of outstanding shares — as of September 30, 2025.
A total of 70 institutional investors currently hold AVTX stock, with a combined institutional value of approximately $194,685,792 as of the most recent 13F filing period.
Frequently asked questions
AVTX ownershipAvalo Therapeutics, Inc. (AVTX) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is BVF INC/IL with a 9.68% stake. Company insiders hold 4.04%. Data sourced from SEC Form 13F as of September 30, 2025.